



## Revolution Medicines to Participate in Upcoming Investor Conferences

February 1, 2024

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6<sup>th</sup> Annual Biotechnology Conference and the TD Cowen 44<sup>th</sup> Annual Health Care Conference.

Details of the company's participation are as follows:

- **Guggenheim Healthcare Talks 6<sup>th</sup> Annual Biotechnology Conference**  
Conference Dates: February 7-8, 2024  
Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, February 7, 2024  
Location: New York, NY; webcast available
- **TD Cowen 44<sup>th</sup> Annual Health Care Conference**  
Conference Dates: March 4-6, 2024  
Fireside Chat Time/Date: 2:10 p.m. Eastern on Wednesday, March 6, 2024  
Location: Boston, MA; webcast available

To access the live webcasts of the presentations, please visit the "Events & Presentations" page of Revolution Medicines' website at <https://ir.revmed.com/events-and-presentations>. Additionally, replays of the webcasts will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following each conference.

### About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company's RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company's development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

Revolution Medicines Media & Investor Contact: Erin Graves 650-779-0136 [egraves@revmed.com](mailto:egraves@revmed.com)